Stimulants prescribed for the treatment of narcolepsy and ADHD are often used ‘off label’ to enhance cognitive function, primarily in the context of a demanding university or workplace. This unprescribed use of neuro-enhancing drugs to maintain competitiveness has even begun to feed back into their marketing. In 2004 pharmaceutical company Cephalon received permission to extend the scope of their product Provigil from ‘excessive daytime sleepiness’ to include ‘shift-work sleep disorder’, which saw sales increase from 196 million dollars in 2002 to 988 million in 2008 (Talbot 2009). Cephalon has also been reprimanded and later pleaded guilty to the off-label promotion of their products as remedies for ‘tiredness’ and ‘decreased activity’.
Martin Lancaster is a former healthcare marketing specialist who worked for international pharmaceutical company Wyeth. He received a Bachelor of Chemistry with first class honours from the Imperial College London, and an MBA in Business, Administration and Marketing from the Macquarie Graduate School of Management. Prior to its consolidation with Pfizer in 2009, he was Wyeth’s regional marketing director within the Asia Pacific region for seven years.
Notable products manufactured by Wyeth include over-the-counter drugs Robitussin―a brand of cough medicine, Advil―an anti-inflammatory analgesic, as well as prescription drugs Premarin―an estrogen medication, and Effexor―trade name for the antidepressant Venlafaxine. Venlafaxine is licenced for use in the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), social phobia, and panic disorder (Australian Medicines Handbook 2013), however it is also used in the treatment of narcolepsy and attention deficit-hyperactivity disorder (ADHD).
Interview Questions
- During your time as marketing director for the Asia Pacific region of Wyeth, were you ever tasked with the marketing of psychiatric drugs like Adderall, Ritalin, or Provigil?
- Were you and your peers aware of the alternate ‘off label’ use of Wyeth’s products? Was this seen as a positive increase of the consumer pool?
- What are your thoughts on the use of prescription drugs for nonmedical purposes?
- In competitive fields there is the risk that abstaining from biological enhancement will put you at a disadvantage. What do you envision the future of high-demand institutions will be like under these circumstances?
- Is there still value in a natural work ethic, or are neuroenhancers simply the next step in an efficient and dedicated work ethic?
- Bio enhancements could also be expanded to include the fitness industry, where performance-enhancing drugs range from commercial supplements to the non-medical use of anabolic steroids, hormones, and stimulants. Are these two contexts comparable?
- Did you notice any change in the popularity and kinds of performance enhancing drugs available during the length of your career? Do you think this has affected your company’s manufacture and marketing of these products?
- Where do you see the development, manufacture, and marketing of performance enhancing drugs 20 years from now?
Citation
Talbot, M. 2009, “Brain gain- the underground world of ‘neuroenhancing’ drugs”, The New Yorker, 27 April, viewed 26 September 2018, < https://www.newyorker.com/magazine/2009/04/27/brain-gain>.



